Copy link
Export CSV
Cite this view
HANK Price Transparency. (n.d.).
RISANKIZUMAB-RZAA 360 MG/2.4 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR (CDM RX-187473) by State .
PPMan price-transparency data, derived from CMS-required hospital MRFs.
Retrieved October 27, 2026 , from http://ppman.hank.ai/transparency/procedure/RX-187473/by-state?code_type=CDM
“RISANKIZUMAB-RZAA 360 MG/2.4 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR (CDM RX-187473) by State.” HANK Price Transparency ,
http://ppman.hank.ai/transparency/procedure/RX-187473/by-state?code_type=CDM. Accessed
October 27, 2026 .
“RISANKIZUMAB-RZAA 360 MG/2.4 ML (150 MG/ML) SUBCUT WEARABLE INJECTOR (CDM RX-187473) by State,” HANK Price Transparency ,
accessed October 27, 2026 ,
http://ppman.hank.ai/transparency/procedure/RX-187473/by-state?code_type=CDM.
Source: PPMan price-transparency data, derived from CMS-required hospital
machine-readable files (45 CFR 180). See
methodology .
Print / Save PDF
CDM · across United States
RX-187473 — Risankizumab-rzaa 360 Mg/2.4 Ml (150 Mg/ml) Subcut Wearable Injector
State-by-state median negotiated rates. Lower bars are cheaper states; the
range bar shows the IQR (25th to 75th percentile within each state).
$50,026
National median
$46,691 – $53,362
IQR (p25 – p75)
2
hospitals filing
1
states
Median negotiated rate, by state
Ranked by typical (median) negotiated price. Hover for state-level IQR.
Median negotiated rate by state for RX-187473 (CDM), with interquartile range
State Median p25 p75
AL $50,026 $46,691 $53,362